Baby KJ was the first to receive a bespoke gene-editing treatment. Personalized drugs for others could be approved within the ...

Cathie Wood’s latest moves entering 2026 focused on early-stage biotechnology firms while cutting exposure to consumer ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the ...

We preselected all newsletters you had before unsubscribing.

SHANGHAI, CHINA, December 5, 2024 /EINPresswire.com/ -- Base Therapeutics has announced that its NK510 cell injection, the world’s first zero-off-target base-edited ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

Cathie Wood is making a massive bet on gene editing, pouring $5.4 billion into companies like Beam Therapeutics while selling ...

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.